McKesson (MCK) Earnings Date & Reports
McKesson is one of three leading pharmaceutical wholesalers in the US engaged in sourcing and distributing branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers... Show more
MCK is expected to report earnings to fall 17.19% to $9.68 per share on August 05
McKesson Corporation (MCK) Q4 Fiscal 2026 Earnings Recap: EPS Beats Offset Revenue Miss
Key Takeaways
- McKesson reported Q4 fiscal 2026 adjusted EPS of $11.69, beating consensus estimates of $11.56 by 1.1%.
- Quarterly revenue reached $96.3 billion, up 6% year-over-year but below expectations of about $101 billion.
- Full-year fiscal 2026 adjusted EPS hit $39.11, up 18% from prior year, surpassing guidance midpoint.
- FY2026 revenue grew 12% to $403.4 billion, driven by oncology and pharmaceutical segments.
- Company issued FY2027 adjusted EPS guidance of $43.80-$44.60, implying 12-14% growth.
- Strong free cash flow of $5.4 billion for FY2026 supported $5.1 billion returned to shareholders.
Earnings Context and Why It Matters
As a leading healthcare distributor, McKesson Corporation (MCK) plays a critical role in the pharmaceutical supply chain, serving hospitals, pharmacies, and providers amid rising demand for specialty drugs and GLP-1 therapies (glucose-like peptide-1 agonists for diabetes and weight management). This Q4 fiscal 2026 report, covering the period ended March 31, 2026, caps a transformative year marked by oncology expansion and portfolio optimization. Investors watch closely for execution in high-margin areas like biopharma services, as industry headwinds such as reimbursement pressures and consolidation persist. Strong results affirm McKesson's ability to generate operating leverage, influencing peers and the broader healthcare sector.
McKesson reported fourth quarter fiscal 2026 revenues of $96.3 billion, a 6% increase from $90.8 billion in the prior-year quarter. This topped year-ago figures but fell short of consensus expectations around $101 billion, primarily due to softer performance in medical-surgical solutions and generic pricing dynamics.
Adjusted earnings per diluted share (EPS) came in at $11.69, surpassing the $11.56 consensus estimate and up 16% year-over-year from $10.12. GAAP EPS was $13.71, compared to $10.01 last year. Key drivers included robust growth in the Oncology & Multispecialty segment (revenues up 35% to $12.7 billion, operating profit up 53%) and North American Pharmaceutical (revenues up 3% to $79.1 billion).
For the full fiscal year 2026, revenues reached $403.4 billion (up 12%), with adjusted EPS of $39.11 (up 18% from $33.05), exceeding the company's prior guidance of $38.80-$39.20. Cash from operations was $6.2 billion, yielding free cash flow (FCF, cash from operations minus capital expenditures) of $5.4 billion. The company returned $5.1 billion to shareholders via repurchases and dividends, including a new $2.25 billion accelerated share repurchase.
Guidance for fiscal 2027 projects adjusted EPS of $43.80 to $44.60. McKesson reaffirmed long-term targets: 13%-16% adjusted EPS compound annual growth rate (CAGR).
AI Screener
Tickeron’s AI Screener is an AI-powered stock and ETF discovery tool that helps traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener identifies trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. Explore it today to enhance your analysis.
Market Reaction and Investor Sentiment
Following the May 7, 2026, release after market close, McKesson shares rose about 1.5% to $754.76 on May 8 open, reflecting optimism over the EPS beat, full-year outperformance, and upbeat FY2027 guidance despite the revenue shortfall. After-hours trading showed a modest 0.85% gain initially. Sentiment remains positive, buoyed by strong oncology growth and capital returns, though revenue miss tempers enthusiasm amid sector volatility.
Forward Outlook and Key Factors to Monitor
McKesson's FY2027 adjusted EPS guidance of $43.80-$44.60 signals continued momentum, with implied 12%-14% growth from FY2026's $39.11. This aligns with reaffirmed long-term targets of 13%-16% EPS CAGR, supported by a focused portfolio emphasizing high-growth areas.
Investors should track the planned separation of the Medical-Surgical Solutions segment, announced with initial financing secured ($1 billion term loan and revolver). This aims to streamline operations toward higher-margin oncology (target 13%-16% operating profit growth) and biopharma services. Prescription Technology Solutions (10%-13% growth target) also warrants attention for software and analytics contributions.
Broader dynamics include GLP-1 drug demand, specialty pharma volumes, and North American Pharmaceutical trends (5%-8% operating profit growth). Margin pressures from generics, reimbursement changes, and M&A integration (mergers and acquisitions) remain risks. Free cash flow generation, now at $5.4 billion annually, underpins shareholder returns via the expanded $7.7 billion repurchase authorization.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
Advertisement
General Information
a distributer of pharmaceuticals and provides healthcare software and health information technology services
Industry MedicalDistributors